Upstream Bio【UPB】銘柄情報

Upstream Bio Inc (UPB) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

7.01

( -5.65% )

買値

7.00

売値

7.02

出来高

440,114

6.995 日の範囲 7.45

6.98 52 週間の範囲 33.68

時価総額

381.484M

前日終値

7.43

始値

7.39

時刻

7.0254

最終取引時間

04:38:05

財務取引量

US$ 3,152,341

VWAP

7.1626

平均取引量 (3 か月)

US$ 726,527

発行済株式数

54,419,986

配当利回り

PER

-2.87

1 株当たり利益 (EPS)

-2.9

歳入

3.32M

純利益

-156.76M

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive ... Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

upstreambio.com

本社

Waltham, United States

設立

2026

Upstream Bio Inc is listed in the Healthcare sector of the ナスダック市場 with ticker UPB. The last closing price for Upstream Bio was US$7.43. Over the last year, Upstream Bio shares have traded in a share price range of US$ 6.98 to US$ 33.68.

Upstream Bio currently has 54,419,986 shares in issue. The market capitalisation of Upstream Bio is US$381.48 million. Upstream Bio has a price to earnings ratio (PE ratio) of -2.87.

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company...

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.3	-15.6438026474	8.31	8.64	6.98	616292	7.71245162	CS
4	-1.87	-21.0585585586	8.88	9.595	6.98	597970	8.40881565	CS
12	-2.31	-24.7854077253	9.32	10.6676	6.98	601585	9.09172903	CS
26	-20.81	-74.8023005032	27.82	33.68	6.98	898450	14.15191213	CS
52	-3.84	-35.3917050691	10.85	33.68	6.98	681263	15.43897687	CS
156	-14.49	-67.3953488372	21.5	33.68	5.14	539870	15.07852755	CS
260	-14.49	-67.3953488372	21.5	33.68	5.14	539870	15.07852755	CS